{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T06:15:41Z","timestamp":1771481741304,"version":"3.50.1"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Mirvetuximab-Soravtansin (MIRV) is an antibody\u2013drug conjugate (ADC) for the therapy of advanced platinum-resistant folate receptor \u03b1 (FR\u03b1)-expressing ovarian cancer. The goal of the study was to treat patients with MIRV off-label in our Comprehensive Cancer Center regarding the outcome and adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective single-center cohort study included six patients with advanced high-grade serous ovarian cancer (HGSOC) or high-grade serous primary peritoneal carcinoma (PPC) with initial FIGO stage IIC\u2013IV between July 2023 and August 2024. Inclusion criteria were metastatic advanced HGSOC or PPC, expression of FR\u03b1 \u226575% (IHC PS2+), and progression during systemic therapy with \u22653 therapies before. All patients underwent ophthalmological examination before therapy with MIRV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After 2\u20136 cycles of MIRV (median, 3.3), objective descriptive response with computed tomography (CT) scan of the thorax\u2013abdomen and CA-125 response were monitored. CA\u2212125 decreased in all evaluable patients (\n                      <jats:italic>n<\/jats:italic>\n                      , 5) from baseline. In the CT scan, two patients showed radiographically stable disease, and one of our patients represented progressive disease. Two patients revealed a partial response, and one of them had partial remission at the initial FIGO stage IV. Adverse events were monitored; one patient developed transient ocular toxicity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Treatment with MIRV has been shown to be promising in advanced ovarian cancer. In a small heterogeneous group of heavily pretreated patients, general recommendations for therapy with MIRV are limited. Close collaboration with ophthalmology and patient education is essential to mitigate ocular events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1732304","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T05:22:54Z","timestamp":1771478574000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment with Mirvetuximab-Soravtansin\u2014first clinical experience in advanced ovarian cancer in a comprehensive cancer center"],"prefix":"10.3389","volume":"16","author":[{"given":"Isabella","family":"Schw\u00f6rer","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Medical Center \u2013 University of Freiburg, Faculty of Medicine","place":["Freiburg, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Huwer","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Medical Center \u2013 University of Freiburg, Faculty of Medicine","place":["Freiburg, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beate","family":"Rautenberg","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Medical Center \u2013 University of Freiburg, Faculty of Medicine","place":["Freiburg, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakob","family":"Neubauer","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology, Medical Center \u2013 University of Freiburg, Faculty of Medicine","place":["Freiburg, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingolf","family":"Juhasz-B\u00f6ss","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Medical Center \u2013 University of Freiburg, Faculty of Medicine","place":["Freiburg, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Jung","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Medical Center \u2013 University of Freiburg, Faculty of Medicine","place":["Freiburg, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2007.11.020","article-title":"Folate receptor alpha as a tumor target in epithelial ovarian cancer","volume":"108","author":"Kalli","year":"2008","journal-title":"Gynecologic Oncol"},{"key":"B3","article-title":"Alpha-folate receptor expression in epithelial ovarian carcinoma and non-neoplastic ovarian tissue","volume":"28","author":"Markert","year":"2008","journal-title":"Anticancer Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.9538","article-title":"Safety and activity of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A phase I expansion study","volume":"35","author":"Moore","year":"2017","journal-title":"J Clin Oncol"},{"key":"B5","volume-title":"Krebs in Deutschland f\u00fcr 2019\/2020. 14. Ausgabe. Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (Hrsg).","author":"Buttmann-Schweiger","year":"2023"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24149","article-title":"Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d\u2019Investigateurs Nationaux Pour les Etudes des Cancers de l\u2019Ovaire (GINECO)","volume":"115","author":"Du Bois","year":"2009","journal-title":"Cancer."},{"key":"B8","volume-title":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren, Langversion 6.1, 2026","year":""},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.08.032","article-title":"Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL)","volume":"163","author":"Gaillard","year":"2021","journal-title":"Gynecologic Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01900","article-title":"Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study","volume":"41","author":"Matulonis","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"B12","volume-title":"Fachinformation ELAHERE, INN-mirvetuximab soravtansine","year":"2025"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-0991","article-title":"FDA approval summary: mirvetuximab soravtansine-gynx for FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"29","author":"Dilawari","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B14","volume-title":"Elahere FDA approval history","author":"Stewart","year":"2024"},{"key":"B15","volume-title":"AbbVie receives european commission approval of ELAHERE","year":"2024"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.11.011","article-title":"The efficacy and safety of mirvetuximab soravtansine in FR\u03b1-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial","volume":"36","author":"Alvarez Secord","year":"2025","journal-title":"Ann Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1097\/ICO.0000000000002934","article-title":"Refractive shifts and changes in corneal curvature associated with antibody-drug conjugates","volume":"41","author":"Canestraro","year":"2022","journal-title":"Cornea."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2023.101155","article-title":"Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine","volume":"47","author":"Hendershot","year":"2023","journal-title":"Gynecologic Oncol Rep"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2474","article-title":"Evaluation of prophylactic corticosteroid eye drop use in the management of corneal abnormalities induced by the antibody-drug conjugate mirvetuximab soravtansine","volume":"25","author":"Matulonis","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"193","DOI":"10.5935\/0004-2749.20140050","article-title":"Is dry eye an environmental disease","volume":"77","author":"Alves","year":"2014","journal-title":"Arq Bras Oftalmol"},{"key":"B21","volume-title":"Fachinformation elahere (Abbvie)","year":"2025"},{"key":"B22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13048-025-01628-z","article-title":"Complete response to Mirvetuximab Soravtansine in platinum-resistant recurrent ovarian cancer: a case report","volume":"18","author":"Wu","year":"2025","journal-title":"J Ovarian Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2025.36.e74","article-title":"FOLR1 as a therapeutic target in platinum-resistant ovarian carcinoma: unique expression patterns across ovarian carcinoma histotypes and molecular subtypes of low-grade serous carcinoma","author":"Leung","year":"2025","journal-title":"J Gynecol Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1732304\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T05:22:55Z","timestamp":1771478575000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1732304\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":23,"alternative-id":["10.3389\/fonc.2026.1732304"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1732304","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"article-number":"1732304"}}